DropXcell Corp.

DropXcell Corp.

Biotechnology Research

Boston, Massachusetts 175 followers

Your X-factor in high-throughput discovery

About us

A Y Innovations Studios Company Screen for function, not binding, of millions of antibodies with droplet microfluidics. Test 1 million antibodies per day for function, such as T cell receptor activation, at 10,000x higher throughput than traditional functional screens. Save 6 months per drug program. Get started faster with our leading expertise in single cell antibody screens and droplet assay optimization, as well as specialized workflows to take you from library generation, through screening, to NGS data analysis.

Website
www.dropxcell.com
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Boston, Massachusetts
Type
Privately Held
Specialties
Droplet microfluidics, Device design, Multi-specific library screens, Novel assay schemas, High-throughput screens, Biologic discovery, Antibody discovery, Single cell assays, Double emulsions, and FACS

Locations

Employees at DropXcell Corp.

Updates

  • DropXcell Corp. reposted this

    View profile for Luke Blauch, PhD, graphic

    Founder of DropXcell | Screening the Function of Millions of Biologics

    What is the #1 thing that pharma CEOs are worried about for 2024? At this years #jpm2024 conference, Accenture hosted a roundtable with CEOs of 12 of the top #pharmaceutical companies, leading to the bold claim that keeping up with advanced technology is their biggest concern for 2024. That's right: the pace of new technology development is so fast, that now CEO's are worried about how they will be able to properly implement these new technologies in order to secure a competitive advantage. Technology--like AI, high-throughput screens, and -omics--is the new competitive frontier in the pharmaceutical industry, and will drive success or failure across the sector. Companies like Amgen believe that they can use technology to cut antibody discovery timelines in half, while Generate Biomedicines' CEO believes that technology will help drug development transform from an artisanal craft to an engineered process. The good news for the CEOs is that companies like DropXcell are here to help. Our expertise in high-throughput, function-focused discovery of antibodies will help the CEOs of the world transform their antibody discovery pipelines to be able to screen millions of antibodies for function, rather than binding. This is poised to be a very exciting 2024 for the industry and for DropXcell, and we look forward to working together to bring new technology to pharmaceutical drug discovery.

    • No alternative text description for this image
  • View organization page for DropXcell Corp., graphic

    175 followers

    Xcell with any #Drop and any #Cell--only with DropXcell. Building a new #antibodydiscovery platform? Every drop has its place, and we know all of them. Work with DropXcell to find and implement the best platform for your personal discovery needs. We can help you with #droplets, assay development, sequencing strategies, and all the other expertise involved in #highthroughput antibody discovery. Have an existing platform? We have expertise in every type of drop and can save you time at the optimization stage to get you screening fast, faster.

    • No alternative text description for this image

Similar pages